BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38740092)

  • 41. Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma.
    Yvon ES; Burga R; Powell A; Cruz CR; Fernandes R; Barese C; Nguyen T; Abdel-Baki MS; Bollard CM
    Cytotherapy; 2017 Mar; 19(3):408-418. PubMed ID: 28109751
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted Delivery of Functionalized Upconversion Nanoparticles for Externally Triggered Photothermal/Photodynamic Therapies of Brain Glioblastoma.
    Tsai YC; Vijayaraghavan P; Chiang WH; Chen HH; Liu TI; Shen MY; Omoto A; Kamimura M; Soga K; Chiu HC
    Theranostics; 2018; 8(5):1435-1448. PubMed ID: 29507632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
    Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
    Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
    Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
    J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TGF-β links glycolysis and immunosuppression in glioblastoma.
    Gong L; Ji L; Xu D; Wang J; Zou J
    Histol Histopathol; 2021 Nov; 36(11):1111-1124. PubMed ID: 34323284
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
    Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
    Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis.
    Huang S; Ding D; Lan T; He G; Ren J; Liang R; Zhong H; Chen G; Lu X; Shuai X; Wei B
    Acta Biomater; 2023 Jul; 164():538-552. PubMed ID: 37037269
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
    Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
    PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
    Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
    PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects.
    Wang X; Ding H; Li Z; Peng Y; Tan H; Wang C; Huang G; Li W; Ma G; Wei W
    Signal Transduct Target Ther; 2022 Mar; 7(1):74. PubMed ID: 35292619
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Internalisation of RGD-Engineered Extracellular Vesicles by Glioblastoma Cells.
    Gečys D; Kazlauskas A; Gečytė E; Paužienė N; Kulakauskienė D; Lukminaitė I; Jekabsone A
    Biology (Basel); 2022 Oct; 11(10):. PubMed ID: 36290387
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma.
    Agliardi G; Liuzzi AR; Hotblack A; De Feo D; Núñez N; Stowe CL; Friebel E; Nannini F; Rindlisbacher L; Roberts TA; Ramasawmy R; Williams IP; Siow BM; Lythgoe MF; Kalber TL; Quezada SA; Pule MA; Tugues S; Straathof K; Becher B
    Nat Commun; 2021 Jan; 12(1):444. PubMed ID: 33469002
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Methotrexate-Loaded Extracellular Vesicles Functionalized with Therapeutic and Targeted Peptides for the Treatment of Glioblastoma Multiforme.
    Ye Z; Zhang T; He W; Jin H; Liu C; Yang Z; Ren J
    ACS Appl Mater Interfaces; 2018 Apr; 10(15):12341-12350. PubMed ID: 29564886
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MicroRNA and extracellular vesicles in glioblastoma: small but powerful.
    Rooj AK; Mineo M; Godlewski J
    Brain Tumor Pathol; 2016 Apr; 33(2):77-88. PubMed ID: 26968172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.
    Zhang L; Zhang Y; Wang X; Zhou Y; Qi J; Gu L; Zhao Q; Yu R; Zhou X
    Small; 2023 Nov; 19(44):e2301439. PubMed ID: 37420326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.